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Summary: A control theory perspective on determination of optimal dynamic treatment regimes is considered. The
aim is to adapt statistical methodology that has been developed for medical or other biostatistical applications so as to
incorporate powerful control techniques that have been designed for engineering or other technological problems. Data
tend to be sparse and noisy in the biostatistical area and interest has tended to be in statistical inference for treatment
effects. In engineering fields, experimental data can be more easily obtained and reproduced and interest is more often
in performance and stability of proposed controllers rather than modelling and inference per se. We propose that
modelling and estimation be based on standard statistical techniques but subsequent treatment policy be obtained
from robust control. To bring focus, we concentrate on A-learning methodology as developed in the biostatistical
literature and H∞-synthesis from control theory. Simulations and two applications demonstrate robustness of the
H∞ strategy compared to standard A-learning in the presence of model misspecification or measurement error.
Key words: A-learning; Anticoagulation; Control; Robust control; H∞-synthesis; Misspecification; Personalized
medicine; Robustness.
This paper has been submitted for consideration for publication in Biometrics
Adaptive Treatment and Robust Control 1
1. Introduction
Murphy (2003) introduced to a wide statistical audience the concepts of optimal dynamic
treatment allocation. In brief, decision rules are sought to allow treatment or other actions
to adapt to accruing information in an optimal way. With increasing interest in personalized
medicine, Murphy’s ideas have been taken up widely in the biostatistical literature and
approaches such as A-learning, Q-learning and outcome-weighted learning have become
popular. These methods are closely related to reinforcement learning in the machine learning
literature, to dynamic programming in general and to other sequential methods such as the
g-computation approach of Robins (1986). Chakraborty and Moodie (2013) provide a good
overview.
Murphy’s original approach is a form of A-learning, with the A standing for advantage,
and under which contrasts between expected outcomes under different treatment regimes
are modelled. Examples include Murphy (2003); Robins (2004); Henderson et al. (2010), and
Henderson et al. (2011). In Q-learning, where Q is taken from quality, the response itself
is modelled at each decision time as a function of history to date, and optimal actions are
determined sequentially (Chakraborty et al., 2013; Laber et al., 2014; Moodie et al., 2014;
Wallace and Moodie, 2015; Song et al., 2015; Linn et al., 2017). A- and Q- learning are
reviewed by Chakraborty and Moodie (2013) and Schulte et al. (2014). Outcome weighted
learning (Zhao et al., 2012; Zhang et al., 2012) is a form of direct search based on direct
estimation of the decision rule itself (Zhao et al., 2015; Zhou et al., 2017). Most of the
methods that have been developed to date are applicable to the case of a binary treatment.
In this paper we are interested in situations in which the treatment can take a large number
of values, such as the dose of a drug, and can be considered as effectively continuous. In
principle both A- and Q-learning and other methods can still apply, and indeed have been
applied by a small number of authors (Rosthøj et al., 2012; Barrett et al., 2014; Rich et al.,
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2014). Outcome learning is more problematic, though we note promising work for single
timepoints by Chen et al. (2016) and also the tree-based approach of Laber and Zhao (2015).
Nonetheless it is clear that this area is much less well developed than the binary treatment
situation.
When treatments are considered as continuous and there are a reasonable number of deci-
sion times, there are close similarities between the dynamic treatment problems considered
in statistics and some of the problems considered by control analysts (Sontag, 1998; Taylor
et al., 2013). Control theory has been useful for a number of statistical problems, such as
optimal experimental design (Pronzato, 2008; Hooker et al., 2015), theoretical analysis of
treatment allocation (Orellana, 2010; Zhang and Xu, 2016), or for control of biomarkers
(Deshpande et al., 2014; Chakrabarty et al., 2017). Still, to our knowledge, rather few of
the vast array of control techniques have been transported into the statistical methodology
literature. To illustrate, R is probably the computing environment that is most used amongst
researchers in statistics. Yet a search of the over 14,000 contributed packages that are publicly
available through the Comprehensive R Archive Network CRAN, showed none at all related
to control theory. In contrast there are multiple toolboxes in MATLAB, which is popular
with engineers, for almost all aspects of control theory.
More specifically, few of the many robust control methodologies have been transported
for optimal dynamic treatment problems, one exception being Bekiroglu et al. (2017), who
proposed a model predictive control approach assuming a sequence of binary treatments
mimicking behavioural change experiments. This is despite the robust control framework
complying well with biostatistical optimal dynamic treatment problems, where there are
multiple sources of uncertainty, including measurement noise, model misspecification, inter-
patient variability and so on. This paper takes a step in this direction by developing so-
called H∞-synthesis for A-learning using Murphy’s regret functions. We selected A-learning
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simply to bring focus: the methods can also be applied to other optimal dynamic treatment
methodologies.
We do not consider modelling, estimation or inference, relying for these on existing A-
learning techniques. Instead, our aim is show how H∞ methods can be applied after the
modelling stage so as to develop treatment rules that are robust to a raft of departures from
the assumed model (Glover and Doyle, 1988; Doyle et al., 1989). These aims are partially
shared with some attempts by statistical researchers to develop either robust or transportable
decision rules (Orellana et al., 2010; Qian and Murphy, 2008; Zhang et al., 2012, 2013;
Wallace et al., 2016; Xu et al., 2016). As will be seen, the methods are very different.
In the next section, we present our general framework, summarise the A-learning methodol-
ogy and show how regret and state-space models can be linked. In Section 3 we concentrate on
linear state-space models and discuss a selection of treatment strategies from the statistical
and control literatures, including a summary of the H∞ approach, with fuller information
provided in supplementary material. In Section 4 we present simulations in which the ap-
proach developed here gives a more robust strategy than a treatment policy derived directly
by application of A-learning. This advantage is confirmed in two applications presented in
Section 5. In the first, our method and standard A-learning procedures are compared using
an experimental ventilation chamber which allows evaluation and comparison of proposed
strategies. In the second, we conduct a retrospective comparison between model-based and
robust anticoagulation decision rules and those selected in practice by clinicians.
2. Preliminaries
2.1 Informal background
We assume that treatment allocations or other decisions are to be made for individual
subjects longitudinally, with the expectation that the choice will depend upon accruing
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information. For a generic subject, assessments are to be made online at times 1, . . . , T . At
time t the available information on the current state of the individual is St. This might be,
for example, a vector of biomarker values, results of a battery of psychological tests, or some
other summary of current condition or change in condition.
Immediately after St becomes known, an action At is selected, such as treatment to be
administered or discontinued, dosage to be applied, or perhaps timing of the next assessment.
For t > 1 let S¯t = (S1, . . . St) and A¯t−1 = (A1, . . . At−1). In addition set S¯1 = S1 and adopt
the convention that A¯0 is null. Hence the information available to the decision maker at
time t is Ht = (S¯t, A¯t−1) and the objective is to develop a decision function dt = dt(Ht)
that proposes an action given the information to hand. A treatment strategy then means a
sequence of decision functions d = {dt}16t6T−1 chosen to meet some overall aim generally
given under the form of an outcome of interest Y (d) to maximise. In our case we restrict
ourselves to the objective of stabilizing a patient state {St} as closely as possible to a target
s∗. For this, we take as outcome:
Y (d) = −
T∑
t=1
{St(d)− s∗}T {St(d)− s∗} = −
T∑
t=1
‖St(d)− s∗‖22, (1)
and the optimal strategy dopt is defined as the maximizer over strategies d of E [Y (d)]. For
simplicity we will assume the target to be time-fixed, but the methods can be extended
to time-varying targets if required. This is a typical objective for long-term maintenance
therapies, such as control of insulin, white blood cell count, CD4 levels or blood clotting
times, as in the example of Section 5.2.
Here Y (d) and St(d) are counterfactuals that would arise if treatment strategy d were
selected. As our focus is not on estimation and inference, we will not introduce any spe-
cial notation for counterfactuals, nor discuss conditions required for causal inference. See
Chakraborty and Moodie (2013) for fuller information and discussion if required.
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2.2 A-learning and regret modelling
A-learning relies on modelling contrasts between expected outcomes under different decision
rules (Schulte et al., 2014; Moodie et al., 2007; Robins, 2004; Rosthøj et al., 2006). The regret
version introduced by Murphy (2003) is based on functions of the form
µt (at | Ht) = E{Y (doptt ) | Ht} − E{Y (at, doptt+1) | Ht} (2)
with doptt = (d
opt
t , . . . , d
opt
T−1). Thus E{Y (doptt ) | Ht} denotes the expected value of Y if the
optimal policy is followed starting from t and if the patient has prior history Ht. In contrast
E{Y (at, doptt+1) | Ht} is the expected value if, given the same prior history, action at is selected
at t but the optimal policy followed thereafter.
The function (2) quantifies the loss made by choosing at as the action at time t instead
of doptt (Ht), and is consequently the regret caused by taking at in comparison with the best
possible decision. Since we have assumed that the objective is to maximize the expected
value of Y , by definition the regret is non-negative and µt(at | Ht) = 0 if and only if at
corresponds to the optimal decision doptt (Ht).
The optimal decision rule is of course unknown. To estimate it, Murphy proposed two
steps:
(1) A parametric form µt (at | Ht) ' µt (at | Ht;ψ) is assumed, and an estimator ψ̂ is
constructed from the data. Usually only a subset of Ht is assumed to be important
and the dimension of ψ is kept modest.
(2) An estimator of the optimal treatment strategy value d̂optt (Ht) is derived by solving the
equation µt(at | Ht; ψ̂) = 0.
The first step is delicate and has been the focus of most research in the biostatistical area.
But once it is achieved, the second step is usually taken as straightforward provided the
regret function is parametrized so that zero is achievable. We simply choose the action that
leads to zero regret.
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2.3 Link with state-space models
To adopt a control theory point of view we need to make a link between µt (at | Ht) and
a state-space model of St. First we introduce some notation. We use St and At to denote
the supports of the state and action variables St and At respectively. Similarly, we define
S¯t and A¯t as the supports of the histories S¯t and A¯t. Recall that the information available
immediately prior to choice of At is Ht =
(
S¯t, A¯t−1
)
and that doptt (Ht) is the optimal but
unknown decision at time t. For r > t now let doptr\t = (d
opt
t+1, . . . , d
opt
r ) be the next r−t optimal
decisions. Obviously these will depend on past values but this is suppressed in the notation.
We will make three assumptions.
A1. The target for maximisation is Y (d) given by (1), that is
Y (d) = −
T∑
t=1
‖St(d)− s∗‖22.
A2. The system evolution linking the next patient state St+1 with its history Ht and the
chosen action At can be described by a state-space model
St+1 = ft(Ht, At) + ε
dyn
t (3)
for some function ft, and with ε
dyn
t a random variable representing stochastic innovations
acting on the system dynamic and independent of (Ht, At). Without loss of generality we
assume E[εdynt ] = 0.
A3. At each time t there is an action which will allow the expected state to reach its target
value. Thus for all S¯t ∈ S¯t and A¯t−1 ∈ A¯t−1, there is an at ∈ At such that
ft(S¯t, A¯t−1, at) = s∗.
Ensuring s∗ is reachable given a state-space model is known as the reachability/controllability
problem in control theory. When the model is linear and time-invariant, a rank condition
on model components has to be satisfied (see Sontag (1998) Chapter 3). For more general
models there is no standardised way to check for controllability, and bespoke methods are
needed for the model and target to hand.
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Each of these assumptions can be relaxed to at least some extent. For example we might
adopt a non-myopic strategy by allowing the target s∗ to be time-varying and always
within the range that is achievable at any time. Then the expected state can be walked
in the desired direction rather than forcing a dramatic short-term change. The assumptions
are kept to allow us to focus on the main ideas rather than considering too much detail
and our results follow from the assumptions as given. Proofs of the propositions are in
supplementary material. The first result relies on the form of Y and the independence of
εdynt from, specifically, the immediately preceding action.
Proposition 1: Under A1 and A2, the regret function at time t ∈ {1, . . . , T −1} has the
general expression
µt (at | Ht) = ‖ft(Ht, at)− s∗‖22 −
∥∥ft(Ht, doptt (Ht))− s∗∥∥22
+
∑T−1
r=t+1 E
{∥∥∥fr(Sr, {At−1, at, doptr\t}) + εdynr − s∗∥∥∥2
2
| Ht
}
−∑T−1r=t+1 E{∥∥∥fr(Sr, {At−1, doptr\(t−1)}) + εdynr − s∗∥∥∥2
2
| Ht
}
.
The addition of assumption A3 leads to a simpler result.
Proposition 2: Under A1, A2 and A3 the regret function at time t ∈ {1, . . . , T − 1} has
the general expression
µt (at | Ht) = ‖ft(Ht, at)− s∗‖22 .
After fitting a regret or other model, a decision strategy can be selected. Performance in
future practice may then be affected by at least three sources of uncertainty.
(1) Parametric uncertainty. Error due to estimation of the assumed parameter values, i.e.
ψ̂ = ψ +4, with 4 an unknown error term.
8 Biometrics, XXXXX 0000
(2) Measurement uncertainty. We may not have access to St but only to noisy observations
St = St + εmt with εmt measurement noise.
(3) Model misspecification: dynamic and model uncertainty. The regret function parametriza-
tion may not be appropriate for the training data, which we think of as model uncertainty.
Or it may be correctly specified for the training data but not fully suitable for all new
patients, which we refer to as dynamic uncertainty.
Parametric uncertainty is of course acknowledged in standard statistical approaches, at
least during the inference stage. In principle, measurement uncertainty can be allowed in
standard optimal dynamic treatment approaches, though in practice this possibility seems
to be overlooked. Model and, particulary, dynamic uncertainty are more problematic from
a statistical viewpoint but these are precisely the forms of disturbances that robust control
policies are designed to give protection against.
3. Treatment Strategies for Linear State-Space Models
3.1 Linear State-Space Model
The definition of a discrete optimal control problem generally requires a state-space model
describing the evolution of St and a cost function to minimize which takes as argument
acceptable treatment strategies d.
A state-space model follows from Proposition 2. As soon as we assume a parametric
formulation for the regret function µt (at | Ht) = µt (at | Ht;ψ), we automatically have a
parametric form for ft(Ht, at) = ft (Ht, at;ψ). In particular we have access to the estimator
fˆt(Ht, at) = ft(Ht, at; ψˆ) with ψ̂ an estimator of ψ obtained by any of the existing methods
for optimal dynamic treatment. For this work, we restrict ourselves to parametric regret
functions of the form:
µt (at | Ht;ψ) = ‖s∗ − FS(ψ)S¯rt − FA(ψ)A¯qt−1 − Fa(ψ)at‖22, (4)
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where S¯rt = (St, St−1, . . . , St−r+1)
T, A¯qt−1 = (At−1, At−2, . . . At−q)
T and FS(ψ), FA(ψ) and
Fa(ψ) are time-constant matrices of appropriate dimension. Proposition 2 then leads, for a
given estimator ψˆ of ψ, to an uncertain linear time-invariant model for the true state St and
its observed version St:
St+1 = FS(ψˆ)S¯
r
t + FA(ψˆ)A¯
q
t−1 + Fa(ψˆ)at + ε
glob
t
St = St + εmt . (5)
Here εglobt = ft(Ht, at) − FS(ψˆ)S¯rt − FA(ψˆ)A¯qt−1 − Fa(ψˆ)at + εdynt represents model misspec-
ification and parametric uncertainty in the state evolution, while εmt is measurement error.
We collect these in the vector
wt =
 εglobt
εmt
 . (6)
having twice the dimension of St.
3.2 Treatment strategies
A decision strategy that produces zero regret would respect ft(S¯t, A¯t−1, d
opt
t (Ht)) = s
∗, which
under (5) would allow the decision rule to be expressed as a linear combination of the elements
in Ht. In control terminology this would be described as a deadbeat strategy. These are little
used in practice, because there is often high variability from one time step to the next and
because of a lack of robustness to any form of uncertainty, including the variants summarised
in Section 2.3. Uncertainty is of course the rule rather than the exception in real applications.
Consequently it is common to accept some underperformance under ideal conditions in return
for robustness in non-ideal circumstances.
One quick and simple alternative would be to change Y (d). For example, we might replace
the outcome Y (d) in (1) with a penalised version
Y (d, λ) = −
T∑
t=1
∥∥St(d, w∗t−1)− s∗∥∥22 − λ‖d(Ht−1)‖22, (7)
with λ a positive constant. Here St(d, w
∗
t−1) is the solution of equation (5) for the treatment
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strategy d, and the sequence w∗t−1 := (w
∗
1, ..., w
∗
t−1) is a realisation of wt up to time t − 1.
Using (7) allows a penalty to be applied to overly-aggressive treatments, assuming that
treatments are parametrized so that small absolute values are preferred, and easily adapted
otherwise. Moreover, the use of a linear state-space representation (5) and the addition of a
Tikhonov regularization term in equation (7) leads our approach to be robust to some level
of misspecification in the way treatment action is modeled (El Ghaoui and Lebret (1997)
and Sra et al. (2012) Chapter 14). At a more theoretical perspective, for a given disturbance
realization w∗T , adding a quadratic penalty term to the input ensures the existence and
uniqueness of the treatment strategy minimizing Y (d, λ) as well as its continuous dependence
with respect to observations. This is a classic result from Linear-Quadratic theory (see Sontag
(1998)).
An alternative approach is to concentrate on directly parametrizing the decision rule itself,
say dt(Ht, β), and then seek the β that gives the optimal policy within this reduced class
of rules, with as few additional assumptions as possible. An important paper in this class is
the robust procedure of Zhang et al. (2013), which builds on Zhang et al. (2012). In brief,
for each candidate value of β we look for the subset of patients in a training data set whose
actual treatments are consistent with the rules dt(Ht, β) at all t. Then we find the β for
which such subsets give good responses. In a little more detail, let Cj = 1 if all decisions for
patient j match those given by dt(Ht, β), with Cj = 0 otherwise. Then in its simplest form
this approach would choose the value of β that maximizes
1
n
n∑
j=1
CjYj
pij(β)
,
where Yj is the observed value of (1) for patient j in a training set of size n, and pij(β)
is a weight function selected to provide consistent estimation. In finite samples of course
rather few patients will have Cj = 1, especially if there are multiple timepoints and multiple
treatment possibilities. More efficient versions are available which make use of more patient
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information (Zhang et al., 2013) but nonetheless the method is not realistic when there are
many treatment options, and is not possible for continuous treatments.
There are a vast number of control theory approaches for bringing robustness. Many, as
above, involve writing down a parametric expression for the decision rule and then either
theoretically or empirically seeking the parameter values that lead to desirable performance.
For example, a simple proportional integral controller is conventionally expressed in the form
dt(Ht, K1, K2) = −K1St −K2
t−1∑
r=1
(Sr − s∗),
with matrices K1 and K2 determining how the rule responds to short and long term re-
sponses respectively. A proportional integral derivative controller extends this by including
an additional term corresponding to the current rate of change, and there are many further
variants.
The method that we will concentrate on for the remainder of this paper is taken from
H∞-synthesis in control theory. Recall that in (5) and (6) we collected all uncertainties in
a vector wt, including measurement error, estimation and modelling errors. We have not so
far made any assumptions about wt other than the additive effect in (5). This is sufficient
for the H∞ approach, which assumes there is an acceptable set D of decision rules and looks
within this set for the rule dinf that minimizes the maximum possible output-to-noise ratio
over all possible non-zero realisations w∗t of wt. Thus
dinf = arg min
d∈D
sup
w∗T−1 6=0
{∑T
t=1
∥∥St(d, w∗t−1)− s∗∥∥22 + λ‖d(Ht−1)‖22∑T−1
t=1 ‖w∗t ‖22
}
. (8)
The goal of this strategy is to reach the target value while uniformly minimizing the impact
of exogenous perturbation on the system. There is no claim of course that dinf will always
lead to good performance when the disturbances are large, but it will provide a least-bad
strategy.
To progress, we obviously need to be able to solve the optimization problem in (8). This
is feasible if we are willing to restrict the set of acceptable strategies D to linear feedback
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form
dt(Ht) = K
1
1 S¯rt−1 +K21 A¯
q
t−1 +K
3
1O
f
t
Oft+1 = K
1
2 S¯rt−1 +K22 A¯
q
t−1 +K
3
2O
f
t , (9)
where Of is an inner state-variable, appearing only in (9) and driven by it. Such restriction
of D ensures we have necessary and sufficient testable criteria for the existence of a solution
for the problem (8), as described in supplementary material. Further, the coefficient matrices
{Kji } can be derived and hence dinf can be obtained, as also summarised in supplementary
material. In practice, given the cost function in (8) and the state-space equation (5), easy-
to-use software is available, such as the hinfsyn function in MATLAB. This produces a
frequency-domain transfer function that can be used to derive the coefficient matrices in (9)
and hence provide a dynamic treatment rule.
4. Simulations
4.1 Experimental design
We have defined dinf to be the H∞ strategy. Let dnom be the regret-based strategy based
on the nominal model assumed in (4). To compare dnom and dinf through simulation we
generated 100 training data sets with scalar states and actions. Each set consisted of 100
longitudinal data sequences of length T = 15. States St were generated using the state-space
model (3) with mean functions
ft(s¯t, a¯t;ψ) = f
∗
t (s¯t, a¯t;ψ) + gt(s¯t, a¯t),
where gt is included in order to simulate model misspecification. Treatments At were drawn
uniformly between -2 and 2, and all targets s∗ were set to zero. After each training data set
was generated, a regret model µi (at | Ht;ψ) was specified and the parameters estimated from
the training data using the regret-regression approach developed by Henderson et al. (2010).
The two treatment policies dnom and dinf were then obtained and applied so as to generate a
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further 100 longitudinal data sequences of the same length T = 15. Actions were determined
by policy but states generated using the same state-space model as for the training data. We
modelled the different kinds of uncertainty as follows.
(1) Model misspecification. To add stochastic disturbance at time t, we took an N(0, σ2d)
distribution for εdynt . In order to imitate model uncertainty, we took as assumed regret
functions
µt (at | Ht, ψ) = {f ∗t (Ht, at;ψ)− s∗}2 ,
so that the functions gt are missing.
(2) Measurement uncertainty. At each time t, we took εmt ∼ N(0, σ2m).
(3) Parametric uncertainty. Instead of ψ, we used in generating dnom and dinf the estimator
ψ̂ obtained from the training data set.
We took the assumed state evolution model to be
f ∗t (s¯t, a¯t;ψ) = ψ1st + ψ2at + ψ3st−1 + ψ4at−1, (10)
with true parameter values (ψ1, ψ2, ψ3, ψ4) = (0.6, 0.2, 0.25, 0.15). For model uncertainty
we assumed an interaction was ignored so gt(s¯t, a¯t) = g1 × st−1at−1. We took four different
values for the coefficient g1, namely 0, 0.005, 0.02 or 0.04, We used three levels each for the
variances of the stochastic perturbations and measurement noise, σ2d = 0, 0.1 or 0.3 and σ
2
m
= 0, 0.1 or 0.3 respectively. Figure 1 gives examples of generated data under these scenarios.
[Figure 1 about here.]
For each scenario and treatment rule we estimated the quantities
ERR {d} = −Egt ,σ2d, σ2m {Y (d)} , VERR {d} = vargt ,σ2d, σ2m {Y (d)} . (11)
The first quantity, ERR, is the negative of the original criterion, and so ideally minimized
by dopt. The second, VERR, is the variance of the outcome computed on the patient set.
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4.2 Sensitivity analysis and adaptive selection method for λ
We now consider the role of the penalty parameter λ in the H∞ strategy (8), and denote
the decision rule as dinfλ so as explicitly to acknowledge the dependence on λ. In the upper
section of Figure 2 we show ERR
{
dinfλ
}
for different values of (g1, σ
2
d, σ
2
m) as λ is varied.
The pattern is similar in all three panels, with the quality of dinfλ quickly increasing with λ
before starting to slowly decreases later. This calls for an adaptive method to select λ.
Given training data HjT =
(
S
s
T , A
s
T−1
)
for j = 1, 2, . . . n, we propose an algorithm based
on scoring the number of occasions at which the H∞ strategy is retrospectively assumed to
provide a better decision than that chosen in practice. We total, over all time points t and
all training data individuals j, the number of occasions on which either
Sjt+1 > s
∗ and dinfλ (H
j
t ) < A
j
t
or
Sjt+1 < s
∗ and dinfλ (H
j
t ) > A
j
t .
We retain the value of λ that corresponds to the highest score. To illustrate, the lower section
of Figure 2 shows how the scores change with λ. The optimal values of λ in the lower plots
would all lead to acceptable decision rules, in that the corresponding ERR
{
dinfλ
}
in the
upper plots are in the low, flat, regions.
[Figure 2 about here.]
4.3 Results
Results are presented in Table 1. Those for dinf are based on use of the algorithm of the
previous subsection for choice of penalty λ. The quantity denoted “Ratio” is the mean value
of
T−1∑
t=1
gt(St, At)
2
f ∗t (St, At)2
,
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which is the ratio of the unknown over the known part of the model computed on the training
set. It is used to quantify the level of misspecification.
When there is little or no model misspecification or uncertainty, dnom slightly outperforms
dinf , as expected, though the performance of dinf is still good. However, as noise and
misspecification levels increase, dinf is much better than dnom in maintaining St close to
target s∗. Further, the low values of VERR for dinf suggest uniform good performance despite
high inter-subject variability.
[Table 1 about here.]
5. Applications
5.1 Ventilation chamber experiment
We tested the dnom and dinf strategies using an experimental ventilation chamber (Taylor,
2004), which allows us to generate training data for the modelling and estimation phase, and
then test data following any of the recommended strategies. Unlike a simulation experiment
there is no known true model, and unlike a standard application we have the opportunity to
test different strategies.
The aim is to control the internal temperature of the chamber by adjusting the voltage
applied to a heating element. Internal temperature is additionally affected by external
temperature, which is not under our control, and by air flow, which is determined in part
by external conditions and in part by two fans inside the chamber, one outlet and one inlet.
In the experiments we considered air flow to represent environmental conditions, with the
outlet fan used to give run-to-run variability and the inlet fan used to add time-varying
noise.
In the following our state St is the difference between ventilation chamber temperature
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and outside temperature, At is the chosen input voltage to the heater, and ε
dyn
t represents
exogenous disturbance due to air flow and potential other unmeasured variables.
To demonstrate use of the heater, the target was set to be 6 C warmer than the outside
temperature i.e s∗ = 6. The first step was to derive from training data an appropriate regret
model within the class (4) and estimate its parameters. As training data we generated 30
trajectories, each of 15 sampling times, and with the input heater voltage At set at either
2V or 4V. The initial choice was random with equal probabilities, and then at samples 5 and
10 we randomly either changed to the alternative voltage or left it at the current value. The
outlet fan input was set at a different level for each trial, selected randomly in the interval
1–3V and held constant throughout the trial. For time-varying disturbances we changed
the voltage to the inlet fan each second, with the changes drawn from a centered Gaussian
distribution with standard deviation 0.2V. Five examples of state and action training data
are given in Figure 3.
[Figure 3 about here.]
We found that a very simple regret model
µt
(
at | H¯t;ψ
)
= (s∗ − ψ1St − ψ2at)2
was adequate for the data, with ψˆ1 = 0.7 and ψˆ2 = 0.5 estimated by using the regret
regression approach proposed by Henderson et al. (2010). From this, we obtain the regret-
based decision rule
dnomt (Ht | ψ) =
s∗ − ψ1St
ψ2
and the uncertain state-space model
St+1 = ψ1St + ψ2at + ε
glob
t ,
which is used to define dinf using the methodology of Section 3.
Next we performed additional trials in which the input voltage, now on a continuous scale,
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was selected using either the regret or H∞ strategies, dnom and dinf respectively. We took
two versions of the H∞ strategy, one with λ = 0.01 and one with λ = 0.001. In each of the
three cases we performed ten new trials, this time of 30 sampling points each. In all cases
the target remained at s∗ = 6 and we set the fan inputs in the same way as for the training
data.
Results are summarised in Table 2 for both the total response over the whole test period
and over the 15 final sampling times. The latter was chosen to represent steady state after
transition from the initial conditions. In terms of average mean square error (MSE) and mean
maximum absolute error (Max E), the H∞ controllers gave better results for both choices
of λ than the regret rule dnom . The difference in performance was more pronounced at the
steady state, that is, once the system is stabilized near the target value.
[Table 2 about here.]
5.2 Warfarin data analysis
We now consider a more typical application of A-learning methodology, which is the choice
of drug dose for patients prescribed Warfarin as long-term anticoagulation prophylaxis. At
each observation time t we take the state St to be the log-transform of the blood clotting
speed, measured through the international normalized ratio (Baglin et al., 2006). We take
the input At to be the prescribed Warfarin dose in mg. If clotting time is too low there is
a risk of thrombosis and an increase in dose is suggested. If clotting time is too high there
is a risk of hemmorrhage and a decrease of dose might be warranted. A typical example of
patient history is given in Figure 4.
[Figure 4 about here.]
Our purpose is to make a retrospective comparison between dose levels that could have
been suggested using regret-based or H∞ strategies with those actually chosen by the
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healthcare providers. The available data consists of the records of 152 patients receiving
Warfarin anticoagulation in Newcastle-upon-Tyne during 2013. Our analyses of the records
indicated no effect of time intervals between clinic visits and so we consider the data as being
in discrete time, indexed by clinic visit number. For our approach we need a sufficient number
of observations for each patient, so we narrowed the analysis to the 120 patients with at least
20 successive measurements. To have data sequences of the same length for comparison, we
took only the first T = 20 entries for each of these patients. We randomly divided the
patients into a training set of 20 patients for calibrating the required models and a testing
set of 100 patients for comparing treatment strategies. This balance was selected because of
our focus on treatment comparison rather than modelling and inference. We repeated the
random selection ten times.
The international normalized ratio is usually considered as acceptable if it lies between
two and three, so we choose as target value s∗ = log(2.5). For each training set we fit the
very simple regret model
µt(at | Ht, ψ) = (s∗ − ψ1St − ψ2at)2 .
More complex functions taking into account past outputs and inputs showed little consistency
between the training sets, which is unsurprising given their small size. Once ψ has been
estimated, we define dnom and dinf as presented in Section 3 for each patient and for each
decision time, using λ = 0.001 for dinf .
For the comparison, we divided the decisions in the test data into three groups, correspond-
ing to when the healthcare provider chose a dose ahpt at time t that seemed to be good, that
seemed to be too low, and that seemed to be too high. We assumed a decision to be good
if blood clotting speed at the next observation time was within the target range of log(2)
to log(3). There were 52% of decisions in this category and in these cases we quantified the
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difference between the chosen dose and each of d = dnom and d = dinf by
GDj,t(d) =
|d(Hj,t)− ahpj,t|
2{d(Hj,t) + ahpj,t}
for patient j at time t.
For 18% of decision times ahpt was followed by a clotting time above the upper limit of the
target range. Here we assume that a lower dose would have been preferred and use
HDj,t(d) = 1{d(Hj,t) < ahpj,t}
as performance measure. For the remaining 30% of decisions ahpt was followed by a clotting
time below the lower limit of the target range and for these we assume that a higher dose
would have been preferred and measure performance through
LDj,t(d) = 1{d(Hj,t) > ahpj,t}.
Table 3 presents the mean values of these statistics, averaged over patients and decision
times, for each of our ten random splits of the data. When the actual decision is acceptable
dnom gives results that are on average closer to those selected by the healthcare provider
than are decisions dinf . In both cases the mean differences are low however. Otherwise, if the
actual decision is poor then dinf outperformed dnom in all ten trials. The actual dinf decisions
were invariably more cautious than dnom when the latter was to recommend a relatively large
change in dose.
In the absence of model or dynamic uncertainty the regret-based policy would be optimal.
In this case the estimated proportion of visits for which the INR would be in the target range
is 67%, which is to be compared with the previously-mentioned observed value of 52%.
[Table 3 about here.]
6. Discussion
We have tried to show how H∞ methods can be of use in dynamic treatment allocation, after
the modelling and estimation stages. We envisage that these and other control methods will
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be of most use in applications involving quantitative choice of drug dosage for patients with
chronic conditions, in which the aim is to maintain a biomarker at, or close to, some target
level. The warfarin application of Section 5.2 provides a typical example. Although not
considered in the paper, covariates can easily be taken into account because the H∞ method
simply takes as input an assumed model. Thus we can build a covariate-dependent model on
training data, and simply input the model with individual-specific covariates at the decision
stage. We do not propose control methods when treatment options are binary or categorical
or when there are few decision times.
For simplicity we have concentrated on the simple cost function (1). More involved, per-
haps asymmetric, costs might be considered in future work, though sometimes a simple
transformation of the response data might be sufficient, such as the use of the logarithm of
blood clotting speed in Section 5.2. Function (1) as given leads naturally to the little-used
deadbeat control and would probably not be selected in engineering applications because of
lack of robustness, as seen in our simulations. We will investigate alternative cost functions,
including integral-of-error components, in future work. We also concentrated in this work on
linear regret models with constant coefficients but note that the methods can be extended
readily to linear Q-learning models. In principle extension to non-linear models and to include
time-varying coefficients is possible, though H∞ control is less well developed for these cases.
There are, however, other robust control methods that could be transportable, including the
non-minimal state-space family (Taylor et al., 2013). Model predictive control is another area
that might very fruitfully be exploited by statisticians. In this approach, at each decision
time a sequence of future decisions is planned rather than just the next, and the sequence is
allowed to change dynamically as new information is provided. It is in some ways close to the
history-adjusted marginal structural modelling methods of van der Laan et al. (2005) and
Petersen et al. (2007), though presented in quite a different manner. In the other direction,
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we suspect that there is not widespread familiarity within the control community of the
latest statistical methods for dealing with noisy or missing observations, or for the careful
consideration of causal effects (Wilson et al., 2018). As control methods are now being
used far beyond traditional engineering applications, and in particular in biomedical areas
where data may be sparse and repeatability is problematic, full attention to modelling and
estimation is becoming ever more important and requires properly grounded and efficient
statistical methodology.
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Figure 1. Example of generated observations for a patient when one value among
(g1, σ
2
d, σ
2
m) is varied while the others are set to 0. The upper plots show the responses
St and lower show the actions At, which are the same in all examples.
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Figure 2. The achieved ERR
{
dinfλ
}
(upper panels) and decision scores (lower panels) as
the penalty λ is varied. The dashed horizontal lines are the values obtained with dnom and
the vertical lines correspond to the λ values giving the highest score.
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Figure 3. Example training trials for ventilation chamber experiment.
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Table 1
Simulation results for both treatment strategies for model (10). ERR and VERR are defined in Eq. (11).(
σ2d, σ
2
m
)
(0, 0) (0, 0.1) (0, 0.3) (0.1, 0) (0.3, 0) (0.1, 0.1) (0.1, 0.3) (0.3, 0.1) (0.3, 0.3)
(a) g1 = 0
Ratio 0 0 0 0 0 0 0 0 0
ERR
{
dinf
}
0.03 0.03 0.08 0.22 1.74 0.23 0.28 1.75 1.84
ERR {dnom} 0.00 0.97 10.36 4.22 7.67 6.80 11.36 9.08 9.35
VERR
{
dinf
}
0.00 0.00 0.00 0.02 0.840 0.02 0.03 0.84 0.99
VERR {dnom} 0.00 9.90 98.75 48.08 48.95 64.08 99.84 66.30 122.89
(b) g1 = 0.005
Ratio 0.24 0.24 0.24 0.24 0.24 0.24 0.24 0.26 0.26
ERR
{
dinf
}
0.03 0.03 0.08 0.22 1.75 0.23 0.28 1.76 1.85
ERR {dnom} 0.00 1.64 11.40 4.30 6.80 7.17 7.66 6.53 11.20
VERR
{
dinf
}
0.00 0.00 0.00 0.02 0.85 0.02 0.03 0.86 1.03
VERR {dnom} 0.00 19.81 139.15 72.41 47.24 73.94 90.88 43.04 87.23
(c) g1 = 0.02
Ratio 0.96 0.97 0.94 0.95 0.94 0.96 0.99 0.93 0.96
ERR
{
dinf
}
0.01 0.03 0.08 0.21 1.74 0.22 0.28 1.74 1.82
ERR {dnom} 0.00 2.20 11.10 4.10 6.12 4.09 10.03 4.34 7.08
VERR
{
dinf
}
0.00 0.00 0.00 0.01 0.85 0.02 0.03 0.82 0.96
VERR {dnom} 0.000 25.51 89.48 55.07 49.84 44.56 120.07 37.35 24.26
(d) g1 = 0.04
Ratio 1.89 1.89 1.88 1.99 2.15 1.92 1.87 1.79 1.93
ERR
{
dinf
}
0.01 0.02 0.09 0.21 1.72 0.22 0.28 1.69 1.80
ERR {dnom} 0.33 3.44 10.56 4.40 6.00 3.90 9.87 5.89 8.52
VERR
{
dinf
}
0.00 0.00 0.00 0.01 0.79 0.01 0.03 0.75 0.89
VERR {dnom} 3.45 43.15 104.40 42.01 55.46 34.62 87.99 59.23 80.17
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Table 2
Summary of test data, using complete sequences (Total) or the final 15 sampling points only (SS), assumed to
represent steady state. MSE is mean squared error between state and target, and max E is the maximum absolute
error.
Method Test no.
Total SS
MSE max E MSE max E
Nominal
1 1.61 4.69 0.18 0.62
2 2.16 5.34 0.21 0.91
3 1.43 4.34 0.32 1.03
4 1.52 4.75 0.22 0.73
5 2.73 5.51 0.14 0.67
6 1.37 4.61 0.26 0.90
7 1.56 4.57 0.17 0.73
8 1.68 4.78 0.25 0.73
9 1.64 4.69 0.20 0.61
10 2.18 5.45 0.14 0.77
Mean 1.79 4.79 0.21 0.77
H∞, λ = 0.01
1 1.49 4.41 0.07 0.50
2 1.27 4.43 0.14 0.75
3 1.23 4.22 0.17 0.78
4 1.11 4.28 0.15 0.72
5 1.22 4.03 0.15 0.63
6 1.19 4.67 0.13 0.52
7 1.67 4.83 0.13 0.73
8 1.38 4.57 0.11 0.50
9 1.20 4.09 0.10 0.50
10 1.41 4.82 0.11 0.56
Mean 1.31 4.43 0.13 0.62
H∞, λ = 0.001
1 0.71 3.63 0.10 0.58
2 1.17 4.16 0.21 0.85
3 1.27 4.25 0.15 0.72
4 1.39 4.64 0.12 0.60
5 1.81 4.77 0.11 0.61
6 1.09 4.25 0.15 0.60
7 1.67 4.69 0.09 0.57
8 1.49 4.43 0.09 0.44
9 2.55 5.39 0.09 0.48
10 1.22 4.69 0.13 0.69
Mean 1.44 4.49 0.12 0.61
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Table 3
Comparison measures between actual and model-based dose levels for Warfarin data. Columns GD(.) measure
average relative distance between good true dose decisions and those proposed by d = dnom and d = dinf . Columns
HD(.) and LD(.) relate to true decisions which led to a dose which is assumed to be too high or too low respectively.
The tabulated values in these columns are the proportions of occasions in which the model-based dose decision is
assumed to be better. Low values of GD are preferred, high values of LD and HD.
Trial GD(dnom) GD(dinf ) HD(dnom) HD(dinf ) LD(dnom) LD(dinf )
1 0.009 0.012 0.42 0.53 0.70 0.77
2 0.009 0.013 0.47 0.59 0.66 0.74
3 0.010 0.014 0.70 0.73 0.44 0.54
4 0.009 0.013 0.45 0.56 0.61 0.70
5 0.009 0.014 0.43 0.54 0.65 0.71
6 0.008 0.012 0.46 0.55 0.66 0.73
7 0.009 0.013 0.48 0.58 0.62 0.70
8 0.010 0.014 0.57 0.68 0.57 0.63
9 0.010 0.014 0.47 0.59 0.66 0.75
10 0.009 0.012 0.45 0.54 0.64 0.75
